Skip to Main Content

Author Details

Rose Hurren
Princess Margaret Cancer Centre
1999
69
32
PMIDPaper TitleJournal TitlePublished Year
37941406Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.Haematologica2024
35668135The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness.Nat Cell Biol2022
33476303A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity.JCI Insight2021
33594052Biological and therapeutic implications of a unique subtype of NPM1 mutated AML.Nat Commun2021
34292323Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.Blood2021
31857370Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia.Haematologica2021
32299104Mitochondrial carrier homolog 2 is necessary for AML survival.Blood2020
33377057Transduction of Primary AML Cells with Lentiviral Vector for <i>In Vitro</i> Study or <i>In Vivo</i> Engraftment.STAR Protoc2020
32416059Disrupting Mitochondrial Copper Distribution Inhibits Leukemic Stem Cell Self-Renewal.Cell Stem Cell2020
32269163The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability.Sci Transl Med2020
30573504The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia.Haematologica2019
29884901Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.Leukemia2019
31617661Global Interactome Mapping of Mitochondrial Intermembrane Space Proteases Identifies a Novel Function for HTRA2.Proteomics2019
31173706The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids.Cell Stem Cell2019
29518628AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.Leuk Res2018
27845271Characterizing the mitochondrial DNA polymerase gamma interactome by BioID identifies Ruvbl2 localizes to the mitochondria.Mitochondrion2017
28283480Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.Blood2017
26732203Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells.Leuk Lymphoma2016
26624983Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.Oncotarget2016
27734609A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.Cancer Med2016
27587383Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.Haematologica2016
27391350A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia.Oncotarget2016
26825710The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice.Blood2016
25820141Mitochondrial DNA damage by bleomycin induces AML cell death.Apoptosis2015
26484416Targeting mitochondrial RNA polymerase in acute myeloid leukemia.Oncotarget2015
26185171Increased pressure alters plasma membrane dynamics and renders acute myeloid leukemia cells resistant to daunorubicin.Haematologica2015
26077472Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death.Cancer Res2015
26158521FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.Cell Death Dis2015
26058080Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.Cancer Cell2015
25832785Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells.Apoptosis2015
25998464Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells.Apoptosis2015
25631767AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress.Blood2015
24273151Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.Am J Hematol2014
24871339A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity.PLoS One2014
24691136Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.PLoS One2014
23318959Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity.Leukemia2013
23520503Metabolic adaptation to chronic inhibition of mitochondrial protein synthesis in acute myeloid leukemia cells.PLoS One2013
23585833Re-directing an alkylating agent to mitochondria alters drug target and cell death mechanism.PLoS One2013
23202731Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.J Clin Invest2013
22488300A genome wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.Apoptosis2012
22957033Suppression of cancer progression by MGAT1 shRNA knockdown.PLoS One2012
21220410The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence.Mol Pharmacol2011
22009536Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.Cancer Res2011
22094260Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.Cancer Cell2011
21513881Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells.Chem Biol2011
21406729Inhibition of SREBP1 sensitizes cells to death ligands.Oncotarget2011
21135258A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.Blood2011
20075161The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma.Blood2010
20644115The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells.Blood2010
20348394The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma.Blood2010
  • 1 - 50 of 69

Recommended Authors

Walter and Eliza Hall Institute of Medical Research
Career Start Year 2016
Number of shared co-authors 1
Huntsman Cancer Institute, The University of Utah
Career Start Year 2013
Number of shared co-authors 1
University of California san francisco
Career Start Year 2011
Number of shared co-authors 0
Zhejiang University Medical Center
Career Start Year 2011
Number of shared co-authors 2
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 2
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 2
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Department of Pharmaceutical Biosciences, Uppsala University
Career Start Year 2009
Number of shared co-authors 0
Huntsman Cancer Institute, University of Utah
Career Start Year 2009
Number of shared co-authors 3
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 2
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 2
Duke University
Career Start Year 2005
Number of shared co-authors 0
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 1
University of Parma
Career Start Year 2003
Number of shared co-authors 1
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 4
Huntsman Cancer Institute, The University of Utah
Career Start Year 2001
Number of shared co-authors 1
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 4
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Comprehensive Cancer Center of Wake Forest Baptist Health, Medical Center Boulevard
Career Start Year 1995
Number of shared co-authors 0
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 3
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 1
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 7
Winship Cancer Institute, Emory University
Career Start Year 1988
Number of shared co-authors 1
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Career Start Year 1987
Number of shared co-authors 2
University of Turin
Career Start Year 1985
Number of shared co-authors 2
Universite Cote d'Azur, INSERM U5
Career Start Year 1982
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 1979
Number of shared co-authors 4
National Cancer Institute
Career Start Year 1978
Number of shared co-authors 0
Mayo Clinic
Career Start Year 1977
Number of shared co-authors 2

Collaborators

Princess Margaret Cancer Centre
Co-authored papers 63
Princess Margaret Cancer Centre
Co-authored papers 48
Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital
Co-authored papers 16
University of Perugia
Co-authored papers 15
The Hospital for Sick Children, University Avenue
Co-authored papers 9
University of Toronto
Co-authored papers 9
University of Toronto
Co-authored papers 7
Ontario Institute for Cancer Research, University Avenue
Co-authored papers 7
The Scripps Research Institute
Co-authored papers 7
Ontario Institute for Cancer Research, University Avenue
Co-authored papers 7
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 6
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
University of Toronto
Co-authored papers 5
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
Princess Margaret Cancer Centre, Ontario Cancer Institute
Co-authored papers 4
University of Waterloo, University Avenue West
Co-authored papers 4
Co-authored papers 3
Princess Margaret Cancer Research Centre
Co-authored papers 3
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
University of Toronto
Co-authored papers 3
Dana-Farber Cancer Institute
Co-authored papers 2
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Hospital for Sick Children, University of Toronto
Co-authored papers 2
Hospital for Sick Children, University of Toronto
Co-authored papers 2
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
University of Kansas Medical Center
Co-authored papers 2
Princess Margaret Cancer Research Centre
Co-authored papers 2
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University Avenue R988
Co-authored papers 2
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 2
University of Toronto
Co-authored papers 2